Eurofins CDMO Alphora Inc. expands its Drug Product Analytical Laboratory

Date de publication :
mercredi, août 14, 2024
Tags :
Newsletter
Eurofins CDMO
Sidra Satti

Sidra Satti, Marketing Specialist, Eurofins CDMO Alphora, sidra.satti@bpt.eurofinsca.com

With a continued focus on the research and development of life-saving therapies and growing customer needs for quality testing, Eurofins CDMO Alphora Inc. has announced the expansion of its Drug Product Analytical Services Facility in Mississauga, Canada. To better serve increasing client demands, Eurofins CDMO Alphora has tripled the size of the facility, incorporating advanced analytical techniques and state-of-the-art instrumentation to enhance support for clients’ drug product programmes.

Scientifique en blouse de laboratoire, lunettes de protection et gants violets utilisant une pipette devant un appareil DISTEK équipé de récipients en verre contenant un liquide clair, illustrant les pratiques de laboratoire rigoureuses chez Eurofins BioPharma Product Testing.

Expansion Highlights

This expansion includes the integration of water activity measurements, intrinsic dissolution studies, additional glovebox systems, added High-Performance Liquid Chromatography (HPLC) instruments, stability chambers, and gas chromatography capabilities. These enhancements aim to bolster the ability to deliver precise, high-quality analytical services tailored to our existing and prospective partners.

Integrated Solutions

With existing drug product capabilities and extensive Solid State Research and Development (SSRD) services, the expanded Drug Product Analytical Laboratory equips Eurofins CDMO Alphora Inc. with the ability to address drug development programme complexities from Phase I through to commercialisation.

Learn More